Fragment-Based Drug Discovery Using Rational Design

Conference paper
Part of the Ernst Schering Foundation Symposium Proceedings book series (SCHERING FOUND, volume 2007/3)


Fragment-based drug discovery (FBDD) is established as an alternative approach to high-throughput screening for generating novel small molecule drug candidates. In FBDD, relatively small libraries of low molecular weight compounds (or fragments) are screened using sensitive biophysical techniques to detect their binding to the target protein. A lower absolute affinity of binding is expected from fragments, compared to much higher molecular weight hits detected by high-throughput screening, due to their reduced size and complexity. Through the use of iterative cycles of medicinal chemistry, ideally guided by three-dimensional structural data, it is often then relatively straightforward to optimize these weak binding fragment hits into potent and selective lead compounds. As with most other lead discovery methods there are two key components of FBDD; the detection technology and the compound library. In this review I outline the two main approaches used for detecting the binding of low affinity fragments and also some of the key principles that are used to generate a fragment library. In addition, I describe an example of how FBDD has led to the generation of a drug candidate that is now being tested in clinical trials for the treatment of cancer.


Virtual Screening Aurora Kinase Fragment Library Biophysical Technique Ligand Efficiency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



I wish to thank all the staff at Astex Therapeutics for allowing me to present their work. In particular, I would thank Dr. Glyn Williams for guidance on the NMR techniques and Dr. Ian Tickle for X-ray crystallography.


  1. Berdini V, O'Reilly M, Congreve MS, Tickle IJ (2007) Fragment-based screening by X-ray crystallography. Jhoti H, Leach AR (eds) Structure-based drug discovery. Springer, Berlin Heidelberg New York, pp 99–123Google Scholar
  2. Beteva A, Cipriani F, Cusack S, Delageniere S, Gabadinho J, Gordon EJ, Guijarro M, Hall DR, Larsen S, Launer L, Lavault CB, Leonard GA, Mairs T, McCarthy A, McCarthy J, Meyer J, Mitchell E, Monaco S, Nurizzo D, Pernot P, Pieritz R, Ravelli RG, Rey V, Shepard W, Spruce D, Stuart DI, Svensson O, Theveneau P, Thibault X, Turkenburg J, Walsh M, McSweeney SM (2006) High-throughput sample handling and data collection at synchrotrons: embedding the ESRF into the high-throughput gene-to-structure pipeline. Acta Cryst D Biol Crystallogr 62:1162–1169CrossRefGoogle Scholar
  3. Blundell TL, Jhoti H, Abell C (2002) High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Disc 1:45–54CrossRefGoogle Scholar
  4. Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, Fong D, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY (2005) A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol 23:201–207PubMedCrossRefGoogle Scholar
  5. Carr R, Jhoti H (2002) Structure-based screening of low-affinity compounds. Drug Discov Today 7:522–527PubMedCrossRefGoogle Scholar
  6. Congreve M, Carr R, Murray C, Jhoti H (2003) A 'rule of three'™ for fragment-based lead discovery? Drug Discov Today 8:876–877PubMedCrossRefGoogle Scholar
  7. Erlanson DA, McDowell RS, O'Brien T (2004a) Fragment-based drug discovery. J Med Chem 47:3463–3482PubMedCrossRefGoogle Scholar
  8. Evrard GX, Langer GG, Perrakis A, Lamzin VS (2007) Assessment of automatic ligand building in ARP/wARP. Acta Cryst D Biol Crystallogr 63:108–117CrossRefGoogle Scholar
  9. Fischer PM, Lane DP (2000) Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr Med Chem 7:1213–1245.Google Scholar
  10. Forstner M, Leder L, Mayr LM (2007) Optimization of protein expression systems for modern drug discovery. Expert Rev Proteomics 4:67–78PubMedCrossRefGoogle Scholar
  11. Gill AL (2004) New lead generation strategies for protein kinase inhibitors – fragment-based screening approaches, Mini-reviews Med Chem 4:301–311Google Scholar
  12. Gill A, Frederickson M, Cleasby A, Woodhead SJ, Carr MG, Woodhead AJ, Walker MT, Congreve MS, Devine LA, Tisi D, Magor LCA, Davis DJ, Curry J, Anthony R, Padova A, Murray CW, Carr RAE, Jhoti H (2005) Identification of novel p38α MAP kinase inhibitors using fragment-based lead generation. J Med Chem 48:414–426PubMedCrossRefGoogle Scholar
  13. Hajduk PJ, Mack JC, Olejniczak ET, Park C, Dandliker PJ, Beutel BA (2004) SOS-NMR: a saturation transfer NMR-based method for determining the structures of protein-ligand complexes. J Am Chem Soc 126:2390–2398PubMedCrossRefGoogle Scholar
  14. Hajduk PJ (2006) Fragment-based drug design: how big is too big? J Med Chem 49:6972–6976PubMedCrossRefGoogle Scholar
  15. Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6:211–219PubMedCrossRefGoogle Scholar
  16. Hann MM, Leach AR, Harper G (2001) Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comp Sci 41:856–864CrossRefGoogle Scholar
  17. Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H (2005) Fragment-based lead discovery using X-ray crystallography. J Med Chem 48:403–413PubMedCrossRefGoogle Scholar
  18. Hopkins AL, Groom CR, Alex A (2004) Ligand efficiency: a useful metric for lead selection. Drug Discovery Today 9:430–431PubMedCrossRefGoogle Scholar
  19. Jahnke W, Erlanson DA (2006) Fragment-based approaches in drug discovery. Wiley-VCHGoogle Scholar
  20. Jhoti H (2003) High-throughput X-ray techniques and drug discovery. In: Waldman H, Koppitz M (eds) Small molecule-protein interactions. (Ernst-Schering Research Foundation) Springer, Berlin Heidelberg New York, pp 43–58Google Scholar
  21. Jhoti H, Leach AR (2007) Structure-based drug discovery. Springer, Berlin Heidelberg New YorkGoogle Scholar
  22. Kuntz ID, Chen K, Sharp KA, Kollman PA (1999) The maximal affinity of ligands. Proc Natl Acad Sci USA 96:9997–10002PubMedCrossRefGoogle Scholar
  23. Lepre CA, Moore JM (2007) Fragment-based NMR Screening in lead discovery. In: Jhoti H, Leach AR (eds) Structure-based drug discovery. Springer, Berlin Heidelberg New York, pp 73–98Google Scholar
  24. Mayer M, Meyer B (2001) Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc 123:6108–6117PubMedCrossRefGoogle Scholar
  25. McCoy MA, Senior MM, Wyss DF (2005) Screening of protein kinases by ATP-STD NMR spectroscopy. J Am Chem Soc 127:7978–7979PubMedCrossRefGoogle Scholar
  26. Mooij WT, Hartshorn MJ, Tickle IJ, Sharff AJ, Verdonk ML, Jhoti H (2006) Automated protein-ligand crystallography for structure-based drug design. Chem Med Chem 1:827–838PubMedGoogle Scholar
  27. Muchmore SW, Olson J, Jones R, Pan J, Blum M, Greer J, Merrick SM, Magdalinos P, Nienaber VL (2000) Automated crystal mounting and data collection for protein crystallography. Structure 8:R243–R246PubMedCrossRefGoogle Scholar
  28. Murray CW, Verdonk ML (2002) The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J Comp-Aided Mol Design 16:741–753CrossRefGoogle Scholar
  29. Nienaber VL, Richardson PL, Klighofer V, Bouska JJ, Giranda VL, Greer J (2000) Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat Biotechnol 18:1105–1108PubMedCrossRefGoogle Scholar
  30. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677–681PubMedCrossRefGoogle Scholar
  31. Oldfield TJ (2001) X-LIGAND: an application for the automated addition of flexible ligands into electron density. Acta Cryst D Biol Crystallogr 57:696–705CrossRefGoogle Scholar
  32. Rees DC, Congreve M, Murray CW, Carr R (2004) Fragment-based lead discovery. Nat Rev Drug Discov 3:660–672PubMedCrossRefGoogle Scholar
  33. Sanchez-Pedregal VM, Reese M, Meiler J, Blommers MJ, Griesinger C, Carlomagno T (2005) The INPHARMA method: protein-mediated interligand NOEs for pharmacophore mapping. Angew Chem Int Ed Engl 44:4172–4175PubMedCrossRefGoogle Scholar
  34. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science 274:1531–1534PubMedCrossRefGoogle Scholar
  35. Stevens RC (2000) High-throughput protein crystallization, Curr Opin Struct Biol 10:558–563Google Scholar
  36. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD (2003) Improved protein-ligand docking using GOLD. Proteins 52:609–623PubMedCrossRefGoogle Scholar
  37. Verlinde CLMJ, Kim H, Bernstein BE, Mande SC, Hol WGJ (1997) in Structure-based drug design. Edited by Veerapandian P. Marcel Dekker, New York, pp. 365–394Google Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Astex Therapeutics Ltd.CambridgeUK

Personalised recommendations